Higher major pathological response seen for patients with resectable NSCLC treated with combo versus durvalumab alone.
Your search for non small cell lung cancer returned 178 results
New research suggests that mRNA COVID-19 vaccines can elevate PD-L1 expression levels in patients with advanced non-small cell lung cancer.
Starting treatment for advanced NSCLC before receiving genomic test results compromises patient outcomes, a study suggests.
Gavreto is an oral tyrosine kinase inhibitor.
Proton pump inhibitor use is associated with shorter survival among patients with non-small cell lung cancer treated with pembrolizumab monotherapy.
Phase 3 trial results support atezolizumab as a potential first-line treatment option for patients with advanced non-small cell lung cancer.
More patients taking alectinib with low-fat yogurt do not reach the exposure threshold of 435 ng/mL
Pemrydi RTU is expected to be available in the first quarter of 2024.
Cancer patients with biomarker-positive tumors have better outcomes on immune checkpoint inhibitor therapy, a meta-analysis suggests.
A regulatory decision is expected on November 27, 2023.